Tuesday - August 4, 2026
Spero Therapeutics Announces Exclusive License with Innovent Biologics for SP001 (IBI355) and $105 Million Non-Recourse, Non-Dilutive Financing Backed by a Portion of Utebzi Milestones and Royalties
July 17, 2026
WASHINGTON, July 17 [Category: BizLaw/Legal] -- WilmerHale, a law firm, posted the following news:

* * *

Spero Therapeutics Announces Exclusive License with Innovent Biologics for SP001 (IBI355) and $105 Million Non-Recourse, Non-Dilutive Financing Backed by a Portion of Utebzi Milestones and Royalties

*

Spero Therapeutics, Inc. (NASDAQ: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunolo . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Click here for more information about our products

Click here for more information about our products